Middle East & Africa In Vivo Cro Market Size & Outlook

The in vivo cro market in Middle East & Africa is expected to reach a projected revenue of US$ 151.3 million by 2030. A compound annual growth rate of 8% is expected of Middle East & Africa in vivo cro market from 2025 to 2030.
Revenue, 2024 (US$M)
$95.4
Forecast, 2030 (US$M)
$151.3
CAGR, 2025 - 2030
8%
Report Coverage
Middle East & Africa

MEA in vivo cro market highlights

  • The MEA in vivo cro market generated a revenue of USD 88.4 million in 2023.
  • The market is expected to grow at a CAGR of 8% from 2024 to 2030.
  • In terms of segment, small molecule was the largest revenue generating modality type in 2023.
  • Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
  • Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.


MEA data book summary

Market revenue in 2023USD 88.4 million
Market revenue in 2030USD 151.3 million
Growth rate8% (CAGR from 2023 to 2030)
Largest segmentSmall molecule
Fastest growing segmentLarge Molecule
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationSmall Molecule, Large Molecule
Key market players worldwideIQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group


Other key industry trends

  • In terms of revenue, MEA region accounted for 1.9% of the global in vivo cro market in 2023.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 823.6 million by 2030.

Small molecule was the largest segment with a revenue share of 63.57% in 2024. Horizon Databook has segmented the Middle East & Africa in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.


An increasing number of R&D projects and life sciences companies in the region is expected to boost market growth during the forecast period. The country is adopting global standards and collaborating with other global CROs to mark its market presence.

Moreover, MEA in vivo CRO industry offers advantages like world-class medical facilities, well-developed infrastructure, and low operational cost, thereby boosting market growth.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

In Vivo CRO Market Scope

In vivo cro market segmentation & scope
Small Molecule
CAR T-cell therapies
CAR-NK cell therapy
TCR-T cell therapy
Others
RNA Therapy
Others
Non GLP
GLP Toxicology
Rat Models
Mice Models
Others
Non-Rodent based
Indication
Autoimmune/inflammation conditions
Rheumatoid Arthritis
Multiple Sclerosis
Osteoarthritis
Irritable Bowel Syndrome
Others
Pain management
Chronic pain
Acute pain
Oncology
Blood cancer
Solid tumor
Syngeneic model
Patient derived xenograft
Xenograft
Others
CNS Conditions
Epilepsy
Parkinson's disease
Huntington's disease
Stroke
Muscular Dystrophy
Alzheimer's Disease
Traumatic brain injury
Amyotrophic lateral sclerosis (ALS)
Spinal Muscular Atrophy
Muscle regeneration
Other Neurodevelopment Disorders
Diabetes
Obesity
Others

In Vivo CRO Market Companies

Name Profile # Employees HQ Website

MEA in vivo cro market size, by country, 2018-2030 (US$M)

Middle East & Africa In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)

MEA in vivo cro market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more